Clinical trialNCT00636519CompletedPhase 1Interventional

Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

SponsorEmergent BioSolutionsEnrollment36Healthy Volunteers

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study is: 1. To evaluate the model determined by the ability of botulism antitoxin (bivalent, Aventis) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage A. 2. To assess the ability of botulism antitoxin (heptavalent, Cangene) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage B.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gordon Peterson, Dr.
Faculty Physicains & Surgeons of Loma Linda University School of Medicine, Department of Neurology
Principal Investigator
clinicaltrials.gov ↗
Richard Sloop, M. D.
R. Richard Sloop, M. D.
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Dr. Gordon Peterson
Loma Linda, California, United States
R. Richard Sloop, M. D.
Yakima, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Botulism Antitoxin Bivalent Types A and BBotulism Antitoxin Heptavalent Types A-G

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Feb 2008
Primary completion: 31 Oct 2009
Completion: 31 Oct 2009
Last update posted: 18 Mar 2024
Registered enrollment: 36
Registry id: NCT00636519

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.